High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction

Jason W. Boland; Elaine G. Boland; David C. Currow

doi:10.1007/s00520-023-07669-8

High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction

Jason W. Boland
, Elaine G. Boland
, David C. Currow

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Abstract

We read with interest this systematic review of the MASCC multidisciplinary recommendations for the management of malignant bowel obstruction in people with advanced cancer (MBO) [1]. Malignant bowel obstruction is difficult to manage and clear guidance is welcome. This article covers important aspects of MBO such as advance care planning and goals of care conversations.

Original language	English
Article number	211
Number of pages	2
Journal	Supportive Care in Cancer
Volume	31
Issue number	4
DOIs	https://doi.org/10.1007/s00520-023-07669-8
Publication status	Published - Apr 2023
Externally published	Yes

Keywords

somastatin analogues
vomiting
malignant bowel obstruction
MASCC

Access to Document

10.1007/s00520-023-07669-8Licence: In Copyright

https://rdcu.be/eRZOgLicence: In Copyright

Cite this

@article{9c176fd49684447e904ecf2207208fed,

title = "High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction",

abstract = "We read with interest this systematic review of the MASCC multidisciplinary recommendations for the management of malignant bowel obstruction in people with advanced cancer (MBO) [1]. Malignant bowel obstruction is difficult to manage and clear guidance is welcome. This article covers important aspects of MBO such as advance care planning and goals of care conversations.",

keywords = "somastatin analogues, vomiting, malignant bowel obstruction, MASCC",

author = "Boland, \{Jason W.\} and Boland, \{Elaine G.\} and Currow, \{David C.\}",

year = "2023",

month = apr,

doi = "10.1007/s00520-023-07669-8",

language = "English",

volume = "31",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "4",

}

TY - JOUR

T1 - High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction

AU - Boland, Jason W.

AU - Boland, Elaine G.

AU - Currow, David C.

PY - 2023/4

Y1 - 2023/4

N2 - We read with interest this systematic review of the MASCC multidisciplinary recommendations for the management of malignant bowel obstruction in people with advanced cancer (MBO) [1]. Malignant bowel obstruction is difficult to manage and clear guidance is welcome. This article covers important aspects of MBO such as advance care planning and goals of care conversations.

AB - We read with interest this systematic review of the MASCC multidisciplinary recommendations for the management of malignant bowel obstruction in people with advanced cancer (MBO) [1]. Malignant bowel obstruction is difficult to manage and clear guidance is welcome. This article covers important aspects of MBO such as advance care planning and goals of care conversations.

KW - somastatin analogues

KW - vomiting

KW - malignant bowel obstruction

KW - MASCC

UR - https://www.scopus.com/pages/publications/85150311400

U2 - 10.1007/s00520-023-07669-8

DO - 10.1007/s00520-023-07669-8

M3 - Letter

C2 - 36917349

AN - SCOPUS:85150311400

SN - 0941-4355

VL - 31

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 4

M1 - 211

ER -

High-quality phase 3 studies do not support the use of somatostatin analogues to reduce vomiting in malignant bowel obstruction

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this